The market is frothing with commotion as hefty investors tug and pull the reins on MorphoSys, signaling a distinct bearish tilt.
Digging into the labyrinth of MorphoSys options history, 27 trades have unfurled their narrative.
Dissecting the tapestry of each transaction, it’s evident that 40% of the trades opened with bullish aspirations while 59% adopted a bearish stance.
From the overarching flurry of trades, 2 puts whispered of a $91,390 whisper, whereas 25 calls trumpeted a grand total of $2,736,244.
Predicted Trajectory of Stock Prices
Following the kaleidoscope of trading sequences, the titans of investment are targeting a price spectrum spanning from $10.0 to $15.0 for MorphoSys in the past three lunar cycles.
Onslaught of Transactional Volume & Interest Flux
In the current market milieu, the mean open interest for MorphoSys options stands valiantly at 2475.62, while the total volume stands at a formidable 36,484.00. The chart maps the ebb and flow of both call and put option volume and open interest for high-value exchanges in MorphoSys, ensconced within the strike price realm from $10.0 to $15.0, across the rolling 30 days.
A Peephole into MorphoSys’s 30-Day Option Volume & Interest Corpus
Monumental Options Trades Unearthed:
| Symbol | PUT/CALL | Transaction Type | Sentiment | Expiry Date | Strike Price | Total Trade Amount | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MOR | CALL | SWEEP | BULLISH | 02/16/24 | $10.00 | $650.0K | 3.7K | 1.1K |
| MOR | CALL | SWEEP | BULLISH | 03/15/24 | $12.50 | $250.0K | 4.1K | 644 |
| MOR | CALL | SWEEP | BEARISH | 02/16/24 | $12.50 | $240.0K | 4.9K | 1.1K |
| MOR | CALL | TRADE | BEARISH | 02/16/24 | $12.50 | $200.1K | 4.9K | 682 |
| MOR | CALL | TRADE | BEARISH | 02/16/24 | $12.50 | $147.0K | 4.9K | 1.7K |
About MorphoSys
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for individuals grappling with cancer and autoimmune afflictions. MorphoSys is propelling its own phalanx of innovative drug contenders and has midwifed antibodies, conceived by partners in diverse arenas of unmet medical exigency. Tremfya (guselkumab) – sired by Janssen Research & Development, LLC and peddled by Janssen Biotech, Inc., to tackle plaque psoriasis – unfurled as the maiden offshoot based on MorphoSys antibody savoir-faire to earn regulatory credence. The U.S. Food and Drug Administration cap-and-gowned the company’s indigenous creation Monjuvi (tafasitamab-cxix) in concert with lenalidomide for patients ensnared in a specific lymphoma tapestry.
Subsequent to our dissection of the antics in the MorphoSys options domain, let us pivot to scrutinize the company’s individual performance.
MorphoSys’s Contemporary Market Standing
- With a trading cavalcade of 31,981,433, the MOR juggernaut stands 1.39% aloft, scaling the zenith at $17.51.
- Gauging existing RSI barometers, the stock seems to be tiptoeing into overbought territory.
- The impending financial report marches onto the scene in 36 days.
Options trading canvasses a peril-pocked terrain, peppered with potential spoils. Cunning traders navigate these tides by perpetually enriching their cognizance, molding their stratagem, monitoring an array of indicators, and vigilantly tracking market pulsations. Keep abreast of the freshest MorphoSys options jigs with real-time triggers from Benzinga Pro.